ReviewCellular & molecular immunology2011
Thymoma and autoimmunity.
Review in Cellular & molecular immunology, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 113 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
113 citing papers in PubMed, 1 synthesis or guideline pooled it, 213 citations in OpenAlex.
- Thymus alterations and susceptibility to immune checkpoint inhibitor myocarditis.Nature medicine · 2023Pooled it
- Primary thymic papillary adenocarcinoma with a rare CD5/CD117-negative and PAX8/WT1-positive immunophenotype: A case report.Oncology letters · 2026Article
- Precision Oncology in Thymic Epithelial Tumors: Therapeutic Horizons and Implementation Barriers.International journal of molecular sciences · 2026Review
- Pure Red Cell Aplasia as an Isolated Paraneoplastic Manifestation of Thymoma: A Case Report and Literature Review.Clinical case reports · 2026Article
- Immune checkpoint inhibitor-related myocarditis in patients with thymic epithelial tumors: a retrospective cohort analysis.Cancer immunology, immunotherapy : CII · 2026Article
- Immune checkpoint inhibitor-associated myocarditis: a novel risk score.European heart journal · 2026Article
- When Central Tolerance Fails: Thymic Malignancies at the Intersection of Cancer Immunity and Autoimmunity.Cancers · 2026Review
- Multi-omics profiling reveals intrathymic triggers and novel biomarkers in thymoma-associated myasthenia gravis.Biomarker research · 2026Article
- Identification of immune cells in benign and malignant thymus tumors: a Mendelian randomization study.Annals of medicine and surgery (2012) · 2026Article
- Fulminant immune checkpoint inhibitor-associated myositis presenting with concurrent myocardial injury and secondary cardiogenic shock in a patient with thymoma: a case report and literature review.Frontiers in cardiovascular medicine · 2026Article
- Case Report: Thymoma-associated stiff person syndrome and myasthenia gravis: an index case with exploratory exome sequencing and review of reported cases.Frontiers in oncology · 2026Article
- Immune-Mediated Multilineage Cytopenias in Thymoma: A Retrospective Case Series.Thoracic cancer · 2026Article
- From tumor immunotherapy to myocardial injury: A mechanistic discussion of immune checkpoint inhibitor‑related myocarditis (Review).Molecular medicine reports · 2025Review
- Pure Red Cell Aplasia Associated With Thymic Tumors, a Nationwide Retrospective Study.American journal of hematology · 2025Article
- Construction of a multimodal artificial intelligence model for differentiating benign and malignant anterior mediastinal tumors.Journal of thoracic disease · 2025Article
- Paraneoplastic minimal change disease in malignant thymoma: a rare association progressing to end-stage renal disease.Oxford medical case reports · 2025Article
- Pure Red Cell Aplasia That Developed 13 Years After Thymoma Treatment: A Case Report and Literature Review.Thoracic cancer · 2025Review
- Article
- Surgical Expert Consensus on Clinical Management of Advanced Thymoma and Thymic Carcinoma: A Beijing-Tianjin-Hebei Collaborative Initiative.Thoracic cancer · 2025Article
- Aberrant Hematopoiesis and CD8Thoracic cancer · 2025Article
53 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The thymus is a central lymphatic organ that is responsible for many immunological functions, including the production of mature, functional T cells and the induction of self-tolerance. Benign or malignant tumors may originate from the thymus gland, with thymoma being the most common and accounting for 50% of anterior mediastinal tumors. Malignancies linked to thymoma include the loss of self-tolerance and the presence of autoimmunity. In this review, we compiled the current scientific evidence detailing the various interactions between thymoma and autoimmune diseases, including myasthenia gravis, systemic lupus erythematosus, inappropriate antidiuretic hormone secretion, pure red cell aplasia, pernicious anemia, pemphigus and autoimmune thyroid diseases. In recent years, several mechanisms have been proposed to explain these interactions. Most are based on the assumption that the 'sick' thymus, like the 'normal' thymus, can generate mature T cells; however, the T cells generated by the sick thymus are impaired and thus may exert cellular autoreactivity. Here, we present several theories that may shed light on the loss of self-tolerance associated with this epithelial tumor of the thymus.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.